203 related articles for article (PubMed ID: 17145606)
41. Cytotoxic and genotoxic monitoring of sickle cell anaemia patients treated with hydroxyurea.
Khayat AS; Antunes LM; Guimarães AC; Bahia MO; Lemos JA; Cabral IR; Lima PD; Amorim MI; Cardoso PC; Smith MA; Santos RA; Burbano RR
Clin Exp Med; 2006 Mar; 6(1):33-7. PubMed ID: 16550342
[TBL] [Abstract][Full Text] [Related]
42. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
43. Hodgkin lymphoma in a sickle cell anaemia child treated with hydroxyurea.
Couronné L; Schneider P; de Montalembert M; Dumesnil C; Lahary A; Vannier JP
Ann Hematol; 2009 Jun; 88(6):597-8. PubMed ID: 18979099
[No Abstract] [Full Text] [Related]
44. Treatment for children with severe aplastic anemia and sickle cell disease in low income countries in Latin America: a report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO): Part III.
Howard SC; Wilimas JA; Flores A; Pacheco C; de Reyes G; Machin S; Svarch E; Navarrete M; Nieves R; Rodriguez H; Masera G;
Pediatr Blood Cancer; 2007 May; 48(5):598-9. PubMed ID: 16883599
[TBL] [Abstract][Full Text] [Related]
45. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy.
Lanaro C; Franco-Penteado CF; Albuqueque DM; Saad ST; Conran N; Costa FF
J Leukoc Biol; 2009 Feb; 85(2):235-42. PubMed ID: 19004988
[TBL] [Abstract][Full Text] [Related]
46. Hydroxycarbamide and erythropoietin in the preoperative management of children with sickle cell anaemia undergoing moderate risk surgery.
Furness CL; O'Driscoll S; Davenport M; Morrison G; Height SE; Dick MC; Rees DC
Br J Haematol; 2009 Feb; 144(3):453-4. PubMed ID: 19036093
[No Abstract] [Full Text] [Related]
47. Sickle cell disease.
Meremikwu M
Clin Evid; 2005 Dec; (14):15-28. PubMed ID: 16620399
[No Abstract] [Full Text] [Related]
48. Sickle cell disease.
Meremikwu M
Clin Evid; 2004 Dec; (12):1-19. PubMed ID: 15865628
[No Abstract] [Full Text] [Related]
49. Sickle cell disease.
Meremikwu M
Clin Evid; 2006 Jun; (15):45-59. PubMed ID: 16973005
[No Abstract] [Full Text] [Related]
50. Proteinuria in children with sickle cell disease.
Marsenic O; Couloures KG; Wiley JM
Nephrol Dial Transplant; 2008 Feb; 23(2):715-20. PubMed ID: 18065783
[TBL] [Abstract][Full Text] [Related]
51. Effect of hydroxyurea on the deformability of the red blood cell membrane in patients with sickle cell anemia.
Athanassiou G; Moutzouri A; Kourakli A; Zoumbos N
Clin Hemorheol Microcirc; 2006; 35(1-2):291-5. PubMed ID: 16899945
[TBL] [Abstract][Full Text] [Related]
52. Effects of oral adenosine 5'-triphosphate and adenosine in enteric-coated capsules on indomethacin-induced permeability changes in the human small intestine: a randomized cross-over study.
Bours MJ; Bos HJ; Meddings JB; Brummer RJ; van den Brandt PA; Dagnelie PC
BMC Gastroenterol; 2007 Jun; 7():23. PubMed ID: 17578566
[TBL] [Abstract][Full Text] [Related]
53. [New issues in adult sickle sell disease].
Girot R; Stankovic K; Lionnet F
Bull Acad Natl Med; 2008 Oct; 192(7):1395-409; discussion 1409-11. PubMed ID: 19445365
[TBL] [Abstract][Full Text] [Related]
54. Hydroxyurea in sickle cell disease.
Adams-Graves P; Heltsley C; Deitcher S
N Engl J Med; 1996 Feb; 334(5):333-4. PubMed ID: 8532043
[No Abstract] [Full Text] [Related]
55. When should hydroxyurea be used for children with sickle cell disease?
Mueller BU
Pediatrics; 2008 Dec; 122(6):1365-6. PubMed ID: 19047256
[No Abstract] [Full Text] [Related]
56. Quantitative analysis of Howell-Jolly bodies in children with sickle cell disease.
Harrod VL; Howard TA; Zimmerman SA; Dertinger SD; Ware RE
Exp Hematol; 2007 Feb; 35(2):179-83. PubMed ID: 17258066
[TBL] [Abstract][Full Text] [Related]
57. Hydroxyurea and new agents for the treatment of sickle cell disease.
Rodgers GP
Clin Adv Hematol Oncol; 2004 Nov; 2(11):713-5. PubMed ID: 16163257
[No Abstract] [Full Text] [Related]
58. Characteristics and outcome of connective tissue diseases in patients with sickle-cell disease: report of 30 cases.
Michel M; Habibi A; Godeau B; Bachir D; Lahary A; Galacteros F; Fifi-Mah A; Arfi S
Semin Arthritis Rheum; 2008 Dec; 38(3):228-40. PubMed ID: 18177923
[TBL] [Abstract][Full Text] [Related]
59. Hydroxycarbamide in sickle cell syndrome: new drug. For severe cases only.
Prescrire Int; 2009 Feb; 18(99):15. PubMed ID: 19388211
[No Abstract] [Full Text] [Related]
60. High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils.
Almeida CB; Traina F; Lanaro C; Canalli AA; Saad ST; Costa FF; Conran N
Br J Haematol; 2008 Sep; 142(5):836-44. PubMed ID: 18564357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
